Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C

摘要

Abstract A fixed-dose combination of the hepatitis C virus (HCV) NS5B polymerase inhibitor sofosbuvir, the HCV NS5A inhibitor velpatasvir and the HCV NS3/4A protease inhibitor voxilaprevir (sofosbuvir/velpatasvir/voxilaprevir; Vosevi_(?)) is approved in the EU for the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection in adults. In the phase III POLARIS trials, in patients who had HCV genotype 1–6 infection with or without compensated cirrhosis, overall rates of sustained virological response at 12?weeks post-treatment (SVR~(12)) with sofosbuvir/velpatasvir/voxilaprevir were high after 8?weeks of treatment in direct-acting antiviral (DAA)-na?ve patients and 12?weeks of treatment in DAA-experienced patients. However, 8?weeks of sofosbuvir/velpatasvir/voxilaprevir was inferior to 12?weeks of sofosbuvir/velpatasvir in cirrhotic or non-cirrhotic DAA-na?ve patients with HCV genotype 1, 2, 4, 5 or 6 infection and non-cirrhotic DAA-na?ve patients with HCV genotype 3 infection, mostly due to an insufficient treatment period. Sofosbuvir/velpatasvir/voxilaprevir was generally well tolerated, with most adverse events being of mild or moderate intensity. The most common adverse events included headache, fatigue, nausea and diarrhoea. In conclusion, sofosbuvir/velpatasvir/voxilaprevir is an important and effective option for the treatment of HCV genotype 1–6 infection in adults, especially those who have previously failed a DAA therapy with or without an HCV NS5A inhibitor.